NCT02417597View on ClinicalTrials.gov

A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)

PHASE4CompletedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Hepatitis E
Interventions
BIOLOGICAL

Recombinant Hepatitis E Vaccine (Escherichia Coli)

Participants would intramuscularly receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) at 0, 1, 6 month.

Trial Locations (1)

Unknown

Kaihua Center for Disease Control and Prevention, Quzhou

All Listed Sponsors
collaborator

Xiamen University

OTHER

collaborator

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

INDUSTRY

lead

Xiamen Innovax Biotech Co., Ltd

INDUSTRY

NCT02417597 - A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli) | Biotech Hunter | Biotech Hunter